All News

Man in window

Sick Leave in axSpA: Who takes more?

Rachel Tate, DO

Who wouldn't like to predict the future? 

Read Article
ACR Best

ACR21 Best Abstracts - Day 1

Jack Cush, MD

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

Read Article
Welder

Work participation in patients with axial spondyloarthritis

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA

Patients with axial spondyloarthritis (axSpA) often have increased absence from work as well as reduced productivity at work, which can have profound impacts for not only the affected individual and their families, but also lead to wider economic and social burden.

Read Article
acr_session2.jpeg

Opening Day Report

Jack Cush, MD

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Read Article
Gout.T2T.jpg

Treat-to-Target Works in Gout With No Cardiac Toxicity

ACR

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of patients reaching target urate levels. Additionally, both appeared safe, with no evidence of increased cardiovascular toxicity (Abstract #1900).

Read Article
Dr Blazer sheds light on the multilayered SDOHs as they affect outcomes in chronic diseases. Head over to #ACR21 https://t.co/Jq7aiRV3MD
Chinny Jumai Osuorji,MD MediaRheum ( View Tweet)
Greater #comorbidity burden is assoc. w/ worse improvement and disease activity in 1st yr of treatment in ERA @earlyarthritis. Comorbidities esp affect SJC and patient and physician global assessments. #ACR21 Abs#0798 @RheumNow https://t.co/02BRqYp9Yk

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

#ACR21 Abst#0285 Calculated 10-yr CV risk ↑ w/in 1st yr of new RA dx in 53 Dutch pts: ➤43% had intermediate (I) or high (H) morbidity risk ➤76% had I or H mortality risk ◘ avg 57yo, 74%♀, 72% HTN, & 57% HLD *️⃣ Early CV risk assessment critical at RA diagnosis! @Rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#ACR21 #Abstr0437 OK, so RTX affects #COVID vaccine but some pts need RTX. Factors predicting response to vaccine: RA vs AAV/IIM Higher IgG Longer time-to-RTX Lower RTX courses Number. Prediction Calculator is developed but need ext. validation #RheumNow https://t.co/iXSaGQ76hS https://t.co/WQAV3GRPBz

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 Ignaki Sanz makes the case that +++ AUTOANTIBODIES are integrally involved in #COVID19 immunopathogeneisis and may rise and fall w disease states- TBD what role they play in acute disease and #LongCovid @CCalabreseDO @VirusesImmunity @CleClinicMD #COVID19AB https://t.co/9dzCSh5V7R
Leonard Calabrese LCalabreseDO ( View Tweet)
Dr. P Krause (FDA/CBER Deputy Dir., Office of Vaccine Research and Review) on #COVIDvaccine in kids: 👉Children respond to vaccine better than adults; can use lower doses 👉the lower dose will mitigate safety concerns (FDA gave EUA for Pfizer vaccine for 5-11 yo) #ACR21 https://t.co/Z7kcYQKZ8S
TheDaoIndex KDAO2011 ( View Tweet)
My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in patients with #SpA, with a focus on abstracts 0380 and 0381 by @ElenaNikiUK #axspa #spondyloarthritis #arthritis #qualityoflife Watch it here👇🏼 https://t.co/MEQ4wkFxrx

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Dr. Eric Yen presenting about lupus nephritis mortality in the USA (1999-2019): - Increasing trend in LN mortality x5 yrs - Increased odds of death for Black pts > Latinx > API > AI/AN - Urbanization (large central metro area) independent RF + effect modifier #ACR21 https://t.co/qf61SkCqw4
Danny Soulsby dsoulsMD ( View Tweet)
Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disability vs SES. Dz severity strong predictor of adverse work outcome despite advanced therapeutic strategies in axSpA. Abs 0381 #ACR21 #RheumNow @RheumNow https://t.co/Lc3yUgXvw6

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Yikes! Higher rates of lupus nephritis deaths in last 5 years 👉8900 lupus nephritis deaths in USA studied race/ethnicity and urbanization assc w/ LN mortality 👉highest in blacks and large central metro regions #ACR21 #Plenary Abstr# 0454 @rheumnow https://t.co/bxQvID8jht
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 #Abstr0454 Mortality rate in #lupus nephritis ⬇️by 26% from 1999-2019👏. BUT, racial and residence disparities were concerning; worse in Black, Hispanic, Asian, AI/AN vs White and in large central and medium metro. Residential matters! @RheumNow https://t.co/33vN39acuL https://t.co/XMwN2hXJn7

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Race/ethnicity and residence were independent risk factors for LN mortality which was higher in: ➡️Black patients ➡️Those living in central metro areas #ACR21 Abst#0454 @RheumNow

Pedro Castillo _Castillo_Pedro ( View Tweet)

Also DESIR cohort: male gender & higher education independently assoc'd w/ lower hazard of Sick Leave (SL.) Older age & higher disease activity assoc'd w/ more SL. AxSpA dz activity & SES play roles in SL predictions. Abs 0380 #ACR21 #RheumNow @RheumNow https://t.co/1lRhDAu7Ug https://t.co/RRG6BeUqvs

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Excited for the first full day of #ACR21, reporting for @RheumNow! Esp looking forward to: ⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes ⭐Plenary session ⭐Scientific sessions covering #axSpA, #PsA and more

Mrinalini Dey DrMiniDey ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×